Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCL-2 Study
NCT05054478Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2021
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in plasma cell leukemia (PCL), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Very Good Partial Response or better at 4 months. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05054478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054478.